Abstract
Ever since immune checkpoint blockade showed activity in the treatment of cancer, the search has been on for combination regimens that make this therapy more effective. In this issue, Blagg and colleagues describe an unorthodox approach to increasing the effectiveness of cancer immunotherapy. See related article by Blagg et al., p. 1649.